MedTrace Logo

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

NCT03735082 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2018-11-08

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast patients

Conditions

Interventions

DRUG

Apatinib

apatinib 250mg,qd,d1-14,14day/cycle

DRUG

Paclitaxel

paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle

DRUG

Carboplatin

carboplatin AUC=4,d1,14day/cycle;

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Qiao Li · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Binghe Xu · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2020-06-01
Completion
2020-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03735082 on ClinicalTrials.gov